CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

Reistone Biopharma

Mayne Pharma

Mayne Pharma is a fast growing company, focused on applying its drug delivery expertise to commercialize branded and generic pharmaceuticals, with operations in Australia and the US. The Company has grown substantially and reflects the hard work and de...

Faraday Pharmaceuticals

Faraday Pharmaceuticals is a biopharmaceutical company pursuing the development of elemental reducing agents (ERAs). This pioneering approach focuses on the ability of specific reduced forms of elements to improve outcomes for patients.

Pfanstiehl

Ion Labs

Ion Labs is a cGMP Certified & FDA registered private label and contract manufacturer of dietary supplements, OTCs, pet supplements, and skin care products.